CN Patent

CN110251512A — 包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法

Assigned to F Hoffmann La Roche AG · Expires 2019-09-20 · 7y expired

What this patent protects

本发明涉及包括给药COBIMETINIB和威罗菲尼的黑色素瘤的组合疗法。本发明总体涉及分子生物学和生长因子调控领域。更具体地，本发明涉及治疗病理学病症(例如癌症)的疗法。更加具体地，本发明涉及包含cobimetinib和威罗菲尼的组合物及其在治疗BRAF‑V600突变阳性的不可切除或转移性黑色素瘤中的用途。

USPTO Abstract

本发明涉及包括给药COBIMETINIB和威罗菲尼的黑色素瘤的组合疗法。本发明总体涉及分子生物学和生长因子调控领域。更具体地，本发明涉及治疗病理学病症(例如癌症)的疗法。更加具体地，本发明涉及包含cobimetinib和威罗菲尼的组合物及其在治疗BRAF‑V600突变阳性的不可切除或转移性黑色素瘤中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN110251512A
Jurisdiction
CN
Classification
—
Expires
2019-09-20
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.